ERBB2 and breast cancer: Although endocrine therapy is recommended for the treatment of metastatic or advanced BC patients with HR+/HER2- as the first-line treatment unless a visceral crisis or life-threatening situation [8, 9], some patients still suffer from recurrence and or suffer from progress due to primary [10] or acquired drugs resistance [11].